Taiho Oncology Announces Multiple Presentations at the ASCO 2016 Annual Meeting

PRINCETON, N.J., May 31, 2016 – Taiho Oncology, Inc. will present clinical data on TAS-102 at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2016.

“These presentations underscore Taiho’s commitment to evaluating potential new therapeutic options for patients with cancer,” said Eric Benn, president and chief executive officer of Taiho Oncology. “We are thrilled to be a part of this year’s meeting and we look forward to opportunities to continue to research and contribute to the growing body of scientific knowledge in oncology.”

Select Presentations

Key TAS-102 data poster presentations are in Hall A during the Gastrointestinal (Noncolorectal) Cancer session Saturday, June 4 from 8:00-11:30 a.m. CT, including:

<table>
<thead>
<tr>
<th>Title</th>
<th>Lead Author</th>
<th>Poster details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer</td>
<td>Atsushi Ohtsu</td>
<td>Abstract #3556 Poster #253</td>
</tr>
<tr>
<td>Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030)</td>
<td>Tomohiro Nishina</td>
<td>Abstract #3557 Poster #254</td>
</tr>
<tr>
<td>Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial</td>
<td>Robert J. Mayer</td>
<td>Abstract #3547 Poster #244</td>
</tr>
<tr>
<td>TAGS, a randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care vs placebo plus best supportive care in patients with metastatic gastric cancer refractory to standard treatments</td>
<td>David H. Ilson</td>
<td>Abstract #TPS4141 Poster #128a</td>
</tr>
</tbody>
</table>

Publication Only

Supportive treatment for hematologic toxicities in the phase 3 RECOURSE trial of TAS-102 vs placebo with best supportive care in patients with metastatic colorectal cancer

Robert J. Mayer

Abstract #e15021

About Taiho Pharmaceutical Co., Ltd. (Japan)

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology,
and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer. In areas other than oncology, as well, the company creates quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical aims to also offer over-the-counter medicinal products that support people’s efforts to lead fulfilling and rewarding lives.

For more information about Taiho Pharmaceutical, please visit: http://www.taiho.co.jp/english/.

About Taiho Oncology, Inc. (U.S.)
Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has established a world class clinical development organization that works urgently to develop innovative cancer treatments and has built a commercial business in the U.S. Taiho has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state of the art facilities are helping us to define the way the world treats cancer. It’s our work; it’s our passion; it’s our legacy.

For more information about Taiho Oncology, please visit: http://www.taihooncology.com.

About Otsuka Holdings Co., Ltd. (Japan)
The Otsuka Group is a global organization of 176 healthcare companies with nearly 43,000 employees (including unconsolidated subsidiaries). Otsuka Holdings Co., Ltd. is the Group’s holding company. The Group operates in 27 countries and regions, conducting diversified businesses in four segments all connected by a focus on health: pharmaceuticals, nutraceuticals, consumer products, and others.

The Group’s corporate philosophy of “Otsuka—people creating new products for better health worldwide,” is supported by the corporate ethic of “JISSHO (Proof through Execution) and SOZOSEI (Creativity).” The Otsuka Group thus seeks to foster a culture and vitality appropriate to an enterprise involved with human health and to create innovative products that contribute to the health and wellness of people worldwide.

For more information, please visit the company's website at http://www.otsuka.com/en/.

###

Media Contact:
Craig Heit
GCI Health on behalf of Taiho Oncology
Taihooncology@gcihealth.com
212-798-9919